Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer

By
Justin.choi
-
0
7
Kite, a Gilead Company and Appia Bio, Inc. announced a collaboration and license agreement to research and develop hematopoietic stem cells-derived cell therapies directed toward hematological malignancies.
[Kite, a Gilead Company]

Sorry, but the selected Zotpress account can't be found.

Press Release